The vaccine can strengthen the body’s immune system, which provides defence against illness and infection. The immune system produces antibodies to limit the spread of HIV when it is unable to stop it. Usually, weak or dead viruses are used to create HIV vaccines. HIV mutates rapidly, and because the vaccination only affects the virus in one form, the vaccine is ineffective. Despite the development of antiretroviral medications for HIV, avoiding HIV infection remains the main objective.
Market Analysis
HIV vaccines were valued at USD 350.01 million in 2021, and it is anticipated that this market would increase to USD 568.92 million by 2030, at a CAGR of 6.24%.
About 35 million individuals are now living with HIV around the world, and since the AIDS epidemic’s inception, about 30 million people have perished from the illness. No one has ever successfully recovered from an HIV infection naturally. In the modern world, there are various types of HIV, and new virus types are constantly emerging. HIV copies itself very quickly. Many scientists are working to understand the precise mechanisms by which the immune system must react to HIV infection. One of the most effective and affordable tools for illness prevention is vaccination. The development of a vaccine that may prevent HIV infection or halt the spread of the disease would significantly aid the fight against it.
HIV prevention education and counselling are crucial topics to include in vaccination campaigns, and even after a vaccine has been made available, there will always be a need for successful behavioural preventive programmes. The global participation of both the public and business sectors is essential to the creation of a preventive HIV vaccine. At this time, neither a government nor a business is supported financially nor encouraged to take the initiative to create an HIV vaccine on their own. The creation of an HIV vaccine is essential for a number of public sector organisations, including those focused on global health, economic development, and international development.
Driving Factors
The increased incidences of HIV infection is the primary factor driving the market’s expansion. Another factor contributing to a favourable outlook on the market’s growth is the population’s growing awareness of the infection. Additionally, market expansion is being fueled by ongoing investments in R&D projects aimed at creating the most effective vaccine. The cost of vaccines and recurrent trial failures, however, can limit market expansion.
The development of antiretroviral therapy as a long-acting suppression (ATLAS), an injectable formulation that has just entered the market and raised the level of care compared to the other medications, is one of the market’s trends.
The expanding number of new product releases and medicinal approvals to spur growth are two major causes. Gilead Sciences, VIIV Healthcare, and other new drug developments are the result of the increased focus on HIV drug research and development. Additionally, there are numerous businesses engaged in global strategic alliances and the development of novel drugs.
Restraining Factors
Lack of medication access and ignorance of HIV infection are two factors that may impede the increase. Despite significant improvements in scientific knowledge and research and development, many HIV-positive individuals still lack access to prompt medical care. There is still no cure for this virus. Furthermore, a lot of people are still ignorant of this sickness. According to a survey by BioMed Central Ltd., of the 478 participants, one-third were ignorant of it; this is the factor that may impede the market’s expansion.
Segmentation Overview
The Global HIV Vaccines Market is segmented on the basis of Type, Antibiotics, And Geography.
- HIV Vaccines Market, By Type
- Pyogenic Paronychia
- Chronic Paronychia
- Candidal Paronychia
- Acute Paronychia
- Others
Based on the Type, the market is segmented into Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia, Acute Paronychia, and Others.
- HIV Vaccines Market, By Antibiotics
- Dicloxacillin
- Fusidic Acid Ointment
- Gentamicin Ointment
- Mupirocin Ointment
- Other
Based on the Antibiotics, the market is bifurcated into Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, Mupirocin Ointment, and Others.
- HIV Vaccines Market, By Geography
- North America
- Europe
- The Asia Pacific
- Rest of the world
The Global HIV Vaccines Market is divided into North America, Europe, Asia Pacific, and the Rest of the World based on regional analysis.
In 2017, North America accounted for more than 44% of the global market. HIV vaccine demand is anticipated to increase significantly between 2017 and 2027 in emerging economies like China and India.
During the projection period, Europe is anticipated to be the largest market. Due to the rise in HIV diagnoses and the concentration of HIV businesses in the area. The increasing strategic partnerships between European businesses will increase drug accessibility, supporting the market’s expansion.
The global market for HIV vaccinations is anticipated to reach $2.7 billion by 2027, according to the Report Ocean report. During the forecast period, moderate growth is anticipated in the Asia-Pacific region.
Target Audience
- Pharmaceutical companies
- Research Laboratories
- Hospitals & Clinics
- Service Suppliers
- Potential Investors
- Key executive (CEO and COO) and strategy growth manager
Opportunities and Challenges
Affordability of HIV Medicines might bring an advent to the process of publicity and ease of approach to all the sections of the society, of different economic situations.
Leading Healthcare Providers Venturing into HIV Space. This step is a very critical opportunity in the growth of the vaccine as we know, the more the distribution and resellers, the more the ease of availability, the more better will be the sale and more importantly, acknowledgement of the vaccine.
Commercialization of HIV Vaccine might pose to a big challenge since HIV belongs to the group of taboos which the community is ashamed to accept. HIV patients around the world are treated as disabled or different. Hence, people need to be educated first, acknowledge and awareness next, accept thereafter and then only the change in the mind-set of the public can be expected. These are the hurdles which need to be passed before even getting into commercializing HIV vaccine and getting into advertisement of the product related.
Key Players in the Market
- AlphaVax, Inc.
- Antigen Express, Inc.
- Argo Therapeutics
- Argos Therapeutics, Inc.
- Bionor Pharmaceuticals
- Celldex Therapeutics, Inc.
- Crucell N.V.
- FIT Biotech
- GeneCure LLC
- Genetic Immunity, Inc.
- GenVec, Inc.
- GeoVax Labs, Inc.
- GlaxoSmithKline plc
- Immune Response BioPharma, Inc.
- Inovio Pharmaceuticals, Inc.
- Novartis AG
- Oncolys Biopharma
- PaxVax
- Profectus Biosciences
- Sanofi SA
- TVAX Biomedical
With a focus on the global market, the “Global HIV Vaccines Market” study report will offer insightful information. Numerous companies, including VIIV healthcare, Gilead Sciences, Inc., GlaxoSmithKline plc, Merck Sharp & Dohme Corp., AbbVie Inc., and Mylan N.V., are prominent market participants. Key development plans, significant market analysis, and successful branding assessment of the aforesaid competitors internationally are included in the competitive landscape section.